Atorvastatin Reduces Proteinuria in Non-Diabetic Chronic Kidney Disease Patients Partly via Lowering Serum Levels of Advanced Glycation End Products (AGEs)

Atorvastatin Reduces Proteinuria in Non-Diabetic Chronic Kidney Disease Patients Partly via Lowering Serum Levels of Advanced Glycation End Products (AGEs)

There is accumulating evidence that advanced glycation end products (AGEs) play a role in the development and progression of chronic kidney disease (CKD). We have previously found that atorvastatin treatment significantly reduces serum levels of AGEs in type 2 diabetic patients and subjects with non...

Full description

Bibliographic Details
Main Authors: Nakamura, Tsukasa, Sato, Eiichi, Fujiwara, Nobuharu, Kawagoe, Yasuhiro, Takeuchi, Masayoshi, Maeda, Sayaka, Yamagishi, Sho-ichi
Format: Online
Language:English
Published: Hindawi Publishing Corporation 2010
Online Access:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3154036/

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3154036/

Similar Items